Immunomodulatory effects of interferons in malignancies

Journal of Interferon and Cytokine Research

Volumn 33, Issue 4, 2013, Pages 154-161

  Bekisz, Joseph ^a   Sato, Yuki ^b   Johnson, Chase ^a   Husain, Syed R ^b   Puri, Raj K ^b   Zoon, Kathryn C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON; LAMBDA INTERFERON; OMEGA INTERFERON; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; CANCER IMMUNOTHERAPY; CELL VIABILITY; DRUG MECHANISM; HUMAN; MONOCYTE; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW;

ANIMALS; CYTOKINES; HUMANS; IMMUNOMODULATION; INTERFERON TYPE I; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MICE; NEOPLASMS;

MUS;

EID: 84876158347     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0167     Document Type: Review

References (50)

1. Andreesen R, Scheibenbogen C, Brugger W, Krause S, Meerpohl HG, Leser HG, Engler H, Lohr GW. 1990. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res 50(23):7450-7456.
2. Baron-Bodo V, Doceur P, Lefebvre ML, Labroquere K, Defaye C, Cambouris C, Prigent D, Salcedo M, Boyer A, Nardin A. 2005. Anti-tumor properties of human-activated macrophages produced in large scale for clinical application. Immunobiology 210(2-4):267-277.
3. Baron S, Finbloom J, Horowitz J, Bekisz J, Morrow A, Zhao T, Fey S, Schmeisser H, Balinsky C, Miyake K, Clark C, Zoon K. 2011. Near eradication of clinically relevant concentrations of human tumor cells by interferon-activated monocytes in vitro. J Interferon Cytokine Res 31(7):569-573.
4. Baron S, Hernandez J, Bekisz J, Poast J, Goldman N, Clouse K, Fields K, Bacot S, Wang J, Zoon K. 2007. Clinical model: interferons activate human monocytes to an eradicative tumor cell level in vitro. J Interferon Cytokine Res 27(2): 157-163.
5. Biswas SK, Sica A, Lewis CE. 2008. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 180(4):2011-2017.
6. Chang CI, Liao JC, Kuo L. 2001. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res 61(3):1100-1106.
7. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC. 2003. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8(3):237-249.
8. Clark RA, Szot S. 1981. The myeloperoxidase-hydrogen peroxide- halide system as effector of neutrophil-mediated tumor cell cytotoxicity. J Immunol 126(4):1295-1301.
9. de Gramont A, Gangji D, Louvet C, Garcia ML, Tardy D, Romet- Lemonne JL. 2002. Adoptive immunotherapy of ovarian carcinoma. Gynecol Oncol 86(1):102-103.
10. Faradji A, Bohbot A, Frost H, Schmitt-Goguel M, Siffert JC, Dufour P, Eber M, Lallot C, Wiesel ML, Bergerat JP, et al. 1991a. Phase I study of liposomal MTP-PE-activated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis. J Clin Oncol 9(7): 1251-1260.
11. Faradji A, Bohbot A, Schmitt-Goguel M, Roeslin N, Dumont S, Wiesel ML, Lallot C, Eber M, Bartholeyns J, Poindron P, et al. 1991b. Phase I trial of intravenous infusion of ex-vivoactivated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects. Cancer Immunol Immunother 33(5):319-326.
12. Galluzzi L, Zamzami N, de La Motte Rouge T, Lemaire C, Brenner C, Kroemer G. 2007. Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis 12(5):803-813.
13. Gaurnier-Hausser A, Rothman VL, Dimitrov S, Tuszynski GP. 2008. The novel angiogenic inhibitor, angiocidin, induces differentiation of monocytes to macrophages. Cancer Res 68(14):5905-5914.
14. Gerrard TL, Siegel JP, Dyer DR, Zoon KC. 1987. Differential effects of interferon-alpha and interferon-gamma on interleukin 1 secretion by monocytes. J Immunol 138(8):2535-2540.
15. Goncharenko-Khaider N, Lane D, Matte I, Rancourt C, Piche A. 2010. The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells. Oncogene 29(40):5523-5536.
16. Gordon S, Taylor PR. 2005. Monocyte and macrophage heterogeneity. Nat Rev Immunol 5(12):953-964.
17. Green DR, Kroemer G. 2004. The pathophysiology of mitochondrial cell death. Science 305(5684):626-629.
18. Hu R, Bekisz J, Hayes M, Audet S, Beeler J, Petricoin E, Zoon K. 1999. Divergence of binding, signaling, and biological responses to recombinant human hybrid IFN. J Immunol 163(2):854-860.
19. Isaacs A, Lindenmann J. 1957. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147(927):258-267.
20. Jessop JJ, Hoffman T. 1993. Production and release of IL-1 beta by human peripheral blood monocytes in response to diverse stimuli: possible role of microdamage to account for unregulated release. Lymphokine Cytokine Res 12(1):51-58.
21. Juo P, Woo MS, Kuo CJ, Signorelli P, Biemann HP, Hannun YA, Blenis J. 1999. FADD is required for multiple signaling events downstream of the receptor Fas. Cell Growth Differ 10(12):797-804.
22. Knight MJ, Riffkin CD, Muscat AM, Ashley DM, Hawkins CJ. 2001. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene 20(41):5789-5798.
23. Kozlowska K, Cichorek M, Wachulska M, Bautembach I. 2006. Role of interleukins and nitric oxide secretion by peritoneal macrophages in differential tumoricidal effect to transplantable melanomas as regarding their biological properties. Immunopharmacol Immunotoxicol 28(2):305-317.
24. LeBlanc HN, Ashkenazi A. 2003. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10(1):66-75.
25. Li M, Liu X, Zhou Y, Su SB. 2009. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 86(1):23-32.
26. Menon C, Bauer TW, Kelley ST, Raz DJ, Bleier JI, Patel K, Steele K, Prabakaran I, Shifrin A, Buerk DG, Sehgal CM, Fraker DL. 2008. Tumoricidal activity of high-dose tumor necrosis factoralpha is mediated by macrophage-derived nitric oxide burst and permanent blood flow shutdown. Int J Cancer 123(2):464-475.
27. Miller CH, Maher SG, Young HA. 2009. Clinical Use of Interferon- gamma. Ann N Y Acad Sci 1182:69-79.
28. Miyake K, Bekisz J, Zhao T, Clark CR, Zoon KC. 2012. Apoptosis- inducing factor (AIF) is targeted in IFN-alpha2a-induced Bid-mediated apoptosis through Bak activation in ovarian cancer cells. Biochim Biophys Acta 1823(8):1378-1388.
29. Monnet I, Breau JL, Moro D, Lena H, Eymard JC, Menard O, Vuillez JP, Chokri M, Romet-Lemonne JL, Lopez M. 2002. Intrapleural infusion of activated macrophages and gammainterferon in malignant pleural mesothelioma: a phase II study. Chest 121(6):1921-1927.
30. Mosser DM, Edwards JP. 2008. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8(12):958-969.
31. Murata M, Nabeshima S, Kikuchi K, Yamaji K, Furusyo N, Hayashi J. 2006. A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine 33(3):121-128.
32. Murdoch C, Lewis CE. 2005. Macrophage migration and gene expression in response to tumor hypoxia. Int J Cancer 117(5): 701-708.
33. Nakashima H, Miyake K, Clark CR, Bekisz J, Finbloom J, Husain SR, Baron S, Puri RK, Zoon KC. 2012. Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumors. Cancer Immunol Immunother 61(7): 1081-1092.
34. Newsom-Davis T, Prieske S, Walczak H. 2009. Is TRAIL the holy grail of cancer therapy? Apoptosis 14(4):607-623.
35. O'Brien J, Lyons T, Monks J, Lucia MS, Wilson RS, Hines L, Man YG, Borges V, Schedin P. 2010. Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am J Pathol 176(3):1241-1255.
36. Paucker K, Cantell K, Henle W. 1962. Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells. Virology 17:324-334.
37. Scarzello AJ, Romero-Weaver AL, Maher SG, Veenstra TD, Zhou M, Qin A, Donnelly RP, Sheikh F, Gamero AM. 2007. A Mutation in the SH2 domain of STAT2 prolongs tyrosine phosphorylation of STAT1 and promotes type I IFN-induced apoptosis. Mol Biol Cell 18(7):2455-2462.
38. Schroder K, Hertzog PJ, Ravasi T, Hume DA. 2004. Interferongamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75(2):163-189.
39. Thiounn N, Pages F, Mejean A, Descotes JL, Fridman WH, Romet-Lemonne JL. 2002. Adoptive immunotherapy for superficial bladder cancer with autologous macrophage activated killer cells. J Urol 168(6):2373-2376.
40. Tsuno T, Mejido J, Zhao T, Phillips T, Myers TG, Bekisz J, Zoon KC. 2012. BID is a critical factor controlling cell viability regulated by IFN-alpha. J Immunother 35(1):23-31.
41. Tsuno T, Mejido J, Zhao T, Schmeisser H, Morrow A, Zoon KC. 2009. IRF9 is a key factor for eliciting the antiproliferative activity of IFN-alpha. J Immunother 32(8):803-816.
42. Uddin S, Platanias LC. 2004. Mechanisms of type-I interferon signal transduction. J Biochem Mol Biol 37(6):635-641.
43. Webb DS, Gerrard TL. 1990. IFN-alpha and IFN-gamma can affect both monocytes and tumor cells to modulate monocytemediated cytotoxicity. J Immunol 144(9):3643-3648.
44. Webb DS, Zur Nedden D, Miller DM, Zoon KC, Gerrard TL. 1989. Enhancement of monocyte-mediated tumoricidal activity by multiple interferon-alpha species. Cell Immunol 124(1):158-167.
45. Wu GS. 2009. TRAIL as a target in anti-cancer therapy. Cancer Lett 285(1):1-5.
46. Wu QL, Buhtoiarov IN, Sondel PM, Rakhmilevich AL, Ranheim EA. 2009. Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia. J Immunol 182(11):6771-6778.
47. Yanase N, Kanetaka Y, Mizuguchi J. 2007. Interferon-alphainduced apoptosis via tumor necrosis factor-related apoptosisinducing ligand (TRAIL)-dependent and -independent manner. Oncol Rep 18(4):1031-1038.
48. Zaidi MR, Merlino G. 2011. The two faces of interferon-gamma in cancer. Clin Cancer Res 17(19):6118-6124.
49. Zhao X, Liu Q, Du B, Li P, Cui Q, Han X, Yan D, Zhu X. 2012. A novel accessory molecule Trim59 involved in cytotoxicity of BCG-activated macrophages. Mol Cells 34(3): 263-270.
50. Zoon KC, ZurNedden, DL, Enterline, JC, Manischewitz, JF, Dyer, DR, Boykins, RA, Bekisz, J, Gerrard, TL. 1986. Chemical and biological characterization of natural human lymphoblastoid interferon alphas. In: Cantell K, Schellekens H, eds. The Biology of the Interferon System. Dordecht:Martinus Nijhoff Pub. pp 567-569.